The Role of Antiangiogenic Drugs in the Treatment of Diabetic Macular Edema

Naimov Dilshod Qayim o’g’li

Abstract

The article presents the characteristics of the first antiangiogenic drug registered for the treatment of diabetic macular edema, ranibizumab, as well as the new long-acting drug brolucizumab.

Full text article

Generated from XML file

Authors

Naimov Dilshod Qayim o’g’li
o’g’li, N. D. Q. (2023). The Role of Antiangiogenic Drugs in the Treatment of Diabetic Macular Edema. Journal of Science in Medicine and Life, 1(4), 97–101. Retrieved from https://journals.proindex.uz/index.php/JSML/article/view/422
Copyright and license info is not available

Article Details

Most read articles by the same author(s)

1 2 > >>